These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16503861)

  • 1. Review of clinical radioimmunotherapy.
    Pohlman B; Sweetenham J; Macklis RM
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):445-61. PubMed ID: 16503861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
    Winter JN
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S22-6. PubMed ID: 15498146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.
    Kawashima H
    ScientificWorldJournal; 2014; 2014():492061. PubMed ID: 25379535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma.
    Macklis RM
    Semin Radiat Oncol; 2007 Jul; 17(3):176-83. PubMed ID: 17591564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    Meredith RF
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
    Witzig TE
    Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):110-7. PubMed ID: 18381106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
    Ghobrial I; Witzig T
    Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma.
    Schaefer-Cutillo J; Friedberg JW; Fisher RI
    Oncology (Williston Park); 2007 Feb; 21(2):203-12; discussion 214, 217, 221. PubMed ID: 17396483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
    J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
    Evens AM; Gordon LI
    Clin Lymphoma; 2004 Oct; 5 Suppl 1():S11-5. PubMed ID: 15498144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus R
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of non-Hodgkin's lymphomas.
    Cheson BD
    Curr Drug Targets; 2006 Oct; 7(10):1293-300. PubMed ID: 17073591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
    Wagner HN; Wiseman GA; Marcus CS; Nabi HA; Nagle CE; Fink-Bennett DM; Lamonica DM; Conti PS
    J Nucl Med; 2002 Feb; 43(2):267-72. PubMed ID: 11850494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert O; Illidge T; Hiddemann W; Dreyling M
    Cancer; 2006 Aug; 107(4):686-95. PubMed ID: 16826593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.